Stockreport

Syros Presents New Preclinical PK and PD Data for SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference

Syros Pharmaceuticals, Inc.  (SYRS) 
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am Check Earnings Report
US:NASDAQ Investor Relations: ir.syros.com
PDF SY-1365 Demonstrates Prolonged PD Effect and Anti-Tumor Activity in Multiple Preclinical Models of Cancer Using Intermittent Dosing, Providing Rationale [Read more]